In November 2024, CMS finalized a 2.83% decrease in the physician fee schedule conversion factor, a key aspect of payment rates under the Medicare program, resulting in a 2.93% decrease in overall payments to physicians and other clinicians. Congress has not yet enacted legislation to address this payment cut, which went into effect on January…
OCR Opens Four Investigations of Medical Schools and Hospitals
SACRAMENTO, California.— Seis años después de asumir el cargo prometiendo ser el “gobernador de la salud” de California, el demócrata Gavin Newsom ha destinado decenas de miles de millones de dólares de fondos públicos a servicios de la red de seguridad para los residentes más necesitados del estado, mientras diseña reglas para hacer que la…
Even the most promising medical advancements struggle to take off in real-world settings without clinician buy-in. Here are some key factors that affect clinician adoption and ways healthtech companies can better position their innovations for success. The post Clinician Adoption: How HealthTech Can Overcome Key Barriers appeared first on MedCity News.
Digital health funding rebounded in the first quarter of 2026, reaching $4 billion across 110 deals, according to data from Rock Health. The surge was fueled mainly by megadeals, reflecting a market where investors are placing larger bets on fewer startups. The post Digital Health Startups Raised $4B in Q1: How Cash Is Flowing Amid…
The way we measure ALS progression is failing patients. We are entering a new era of ALS therapeutics but still relying on the same blunt instruments of measurement. The post In the Absence of Objective Measures for ALS, Caregivers are the Only Witnesses. We Shouldn’t Have To Be. appeared first on MedCity News.
Medicare has launched a temporary program covering GLP-1s for obesity for people with Medicare, known as the Medicare GLP-1 Bridge. This analysis estimates the number of Medicare Part D enrollees who could potentially qualify for the Bridge program by meeting all of the eligibility criteria, based on claims data from 2023.
Merus brings Genmab a bispecific antibody in two pivotal studies for head and neck cancer. Genmab, which had long developed drugs under partnerships with larger companies, is now pursuing a strategy of developing and commercializing medications it fully owns. The post Genmab to Pay $8B to Get Its Hands on Merus Head & Neck Cancer…
Four key predictions for the future of clinical trials, examining how these changes will revolutionize the speed, efficiency, and reliability of bringing life-saving treatments to market. The post Future Trends for Clinical Trials in 2025 and Beyond appeared first on MedCity News.
Letters to the Editor is a periodic feature. We welcome all comments and will publish a selection. We edit for length and clarity and require full names. A chronic-pain patient advocate, who has been featured previously in KFF Health News coverage, spoke out on the social platform X about our “Payback: Tracking the Opioid Settlement Cash” project: Oh,…